| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Coastlands Capital Partners LP | 9.3% | $2,984,854 | 2,815,900 | Coastlands Capital LP | 28 May 2025 | |||
| Adjuvant Global Health Technology Fund, L.P. | 7.9% | $3,227,960 | 2,373,500 | Adjuvant Capital GP, L.P. | 31 Dec 2024 | |||
| Easom Eric | 6.2% | $2,574,660 | 1,893,132 | Eric Easom | 31 Dec 2024 | |||
| Almitas Capital LLC | 5.2% | $1,813,970 | 1,428,323 | Almitas Capital LLC | 30 Sep 2025 | |||
| Brii Biosciences Ltd | 3.1% | $1,260,993 | 927,201 | Brii Biosciences Limited | 31 Dec 2024 | |||
| BML Investment Partners, L.P. | 1.4% | -85% | $551,387 | -$3,599,088 | 427,432 | -87% | BML Investment Partners, L.P. | 17 Jun 2025 |
As of 30 Sep 2025, 35 institutional investors reported holding 8,276,317 shares of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX). This represents 30% of the company’s total 27,467,750 outstanding shares.
The largest institutional shareholders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) together control 30% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Almitas Capital LLC | 5.2% | 1,428,323 | 0% | 0.42% | $1,813,970 |
| VANGUARD GROUP INC | 3.9% | 1,080,070 | +4.3% | 0% | $1,371,689 |
| Pfizer Inc | 2.6% | 715,295 | 0% | 0.21% | $908,425 |
| Peapod Lane Capital LLC | 2.1% | 589,216 | +1.1% | 0.67% | $748,317 |
| Stonepine Capital Management, LLC | 2.1% | 563,913 | +3.6% | 0.58% | $716,170 |
| BANK OF NOVA SCOTIA | 1.7% | 459,194 | 0% | 0% | $583,176 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 1.7% | 456,463 | -7.9% | 0.04% | $579,708 |
| BANK OF MONTREAL /CAN/ | 1.5% | 422,077 | 0% | 0% | $536,038 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 385,597 | -3.3% | 0% | $489,708 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 385,310 | -0.05% | 0% | $489,343 |
| BlackRock, Inc. | 1.2% | 320,911 | +0.51% | 0% | $407,557 |
| TWO SIGMA ADVISERS, LP | 0.98% | 267,900 | -0.63% | 0% | $340,233 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.91% | 249,351 | 0% | 0% | $316,747 |
| TWO SIGMA INVESTMENTS, LP | 0.81% | 223,337 | -6.3% | 0% | $283,638 |
| MORGAN STANLEY | 0.69% | 190,770 | +7% | 0% | $242,278 |
| STATE STREET CORP | 0.32% | 87,002 | 0% | 0% | $110,493 |
| Rangeley Capital, LLC | 0.24% | 65,000 | 0% | 0.08% | $82,550 |
| Squarepoint Ops LLC | 0.23% | 64,267 | +539% | 0% | $81,619 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.22% | 59,900 | 0% | 0% | $76,073 |
| UBS Group AG | 0.21% | 56,694 | -8.6% | 0% | $72,001 |
| NORTHERN TRUST CORP | 0.16% | 43,196 | 0% | 0% | $54,859 |
| CAPTRUST FINANCIAL ADVISORS | 0.15% | 40,000 | 0% | 0% | $50,800 |
| CITADEL ADVISORS LLC | 0.08% | 23,013 | +84% | 0% | $29,227 |
| Private Advisor Group, LLC | 0.08% | 22,500 | 0% | 0% | $28,575 |
| XTX Topco Ltd | 0.07% | 18,541 | -29% | 0% | $23,547 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$23,113 | $1.16 | 0 |
| 2025 Q3 | 8,276,317 | $10,511,010 | +$7,412 | $1.27 | 35 |
| 2025 Q2 | 8,284,557 | $8,781,263 | -$781,030 | $1.06 | 36 |
| 2025 Q1 | 14,340,830 | $19,503,615 | -$264,700 | $1.36 | 37 |
| 2024 Q4 | 14,528,930 | $20,049,919 | +$893,480 | $1.38 | 37 |
| 2024 Q3 | 13,513,224 | $14,458,906 | -$16,315,893 | $1.07 | 31 |
| 2024 Q2 | 19,415,909 | $41,730,123 | +$373,518 | $2.15 | 45 |
| 2024 Q1 | 1,582,719 | $5,124,476 | -$14,962,317 | $3.25 | 3 |
| 2023 Q4 | 0 | $0 | -$17,045 | $1.16 | 0 |
| 2023 Q3 | 19,931,490 | $320,311,244 | +$132,978,059 | $16.08 | 37 |
| 2023 Q2 | 11,741,328 | $99,891,308 | +$18,089,480 | $8.50 | 30 |
| 2023 Q1 | 9,600,229 | $94,752,922 | -$1,674,217 | $9.87 | 37 |
| 2022 Q4 | 9,762,608 | $93,038,255 | -$3,679,710 | $9.53 | 35 |
| 2022 Q3 | 9,456,495 | $164,353,000 | +$2,103,098 | $17.38 | 34 |
| 2022 Q2 | 9,286,671 | $71,557,000 | +$2,306,823 | $7.75 | 28 |
| 2022 Q1 | 8,951,852 | $134,101,000 | +$134,100,862 | $15.07 | 17 |